CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable 
ERBB2:ERBB3 heterodimerization

Werr, Lisa; Plenker, Dennis; Dammert, Marcel A.; Lorenz, Carina; Bragelmann, Johannes; Tumbrink, Hannah L.; Klein, Sebastian; Schmitt, Anna; Buttner, Reinhard; Persigehl, Thorsten; Shokat, Kevan M.; Wunderlich, Frank Thomas; Schram, Alison M.; Peifer, Martin; Sos, Martin L.; Reinhardt, Hans Christian; Thomas, Roman K.

doi:10.1158/1535-7163.MCT-21-0820

Item

ITEM ACTIONSEXPORT

DownloadE-Mail

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_3386051_2

DetailsSummary

CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization

Werr, L., Plenker, D., Dammert, M. A., Lorenz, C., Bragelmann, J., Tumbrink, H. L., et al. (2022). CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Molecular Cancer Therapeutics, 21(5), 821-830. doi:10.1158/1535-7163.MCT-21-0820.

Item is Released

show all hide all

Basic

show hide

Item Permalink: https://hdl.handle.net/21.11116/0000-000A-878C-0 Version Permalink: https://hdl.handle.net/21.11116/0000-000A-878D-F

Genre: Journal Article

Files

show Files

Locators

show

Creators

show

hide

Creators:
Werr, Lisa, Author
Plenker, Dennis, Author
Dammert, Marcel A., Author
Lorenz, Carina, Author
Bragelmann, Johannes, Author
Tumbrink, Hannah L., Author
Klein, Sebastian, Author
Schmitt, Anna, Author
Buttner, Reinhard, Author
Persigehl, Thorsten, Author
Shokat, Kevan M., Author
Wunderlich, Frank Thomas¹, Author
Schram, Alison M., Author
Peifer, Martin², Author
Sos, Martin L.², Author
Reinhardt, Hans Christian³, Author
Thomas, Roman K.², Author

Affiliations:
1Obesity and Cancer, Department Jens Brüning, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149645
2Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656
3Neuronal Control of Metabolism, Department Jens Brüning, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149644

Content

show

Details

show

hide

Language(s): eng - English

Dates: Date issued: 2022

Publication Status: Issued

Pages: -

Publishing info: -

Table of Contents: -

Rev. Type: Peer

Identifiers: DOI: 10.1158/1535-7163.MCT-21-0820

Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show

hide

Title: Molecular Cancer Therapeutics

Other : Mol. Cancer Ther.

Source Genre: Journal

Creator(s):

Affiliations:

Publ. Info: Philadelphia, PA : American Association for Cancer Research, Inc.

Pages: - Volume / Issue: 21 (5) Sequence Number: - Start / End Page: 821 - 830 Identifier: ISSN: 1535-7163
CoNE: https://pure.mpg.de/cone/journals/resource/111022849554084